Treatment of benign prostatic hyperplasia with transurethral electrovaporization of the prostate (TUVP) using Vaportrode VE-B: Two years follow-up

M. Diana, M. Schettini, M. Gallucci

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background. The authors report their experience on transurethral vaporization of the prostate with Vaportode for the treatment of BPH. Methods. In January 1996 we treated 24 patients suffering from cervico-urethral obstruction caused by BPH with electrovaporization of the prostate using a cutting current of between 180 and 250 Watts (average 200 Watts). Exclusion criteria was: PSA>3 ng/ml. The catheter was removed after 24 hours. Follow-up of all patients is 27 months. Twenty-three patients were evaluated. Results. Results at follow-up were; mean maximum flow (Qmax) 9.31 ml/sec preoperative was 19.5 ml/sec after 6 months, 18.3 after 12 months and 18.0 after 24 months; mean symptom score decreased from 18.1 to 10.4 after 6 months, to 3.2 after 12 months and to 4.8 after 24 months; QL index decreased from 4.6 to 2.3 at 6 months, to 1.4 after 12 months and 24 months; the average avoiding pressure decreased from 62.8 cm/H2O to 23.2 cm/H2O after 6 months, to 21.2 after 12 months and to 23.8 after 24 months. There was no post voiding residual urine 2 days after treatment in all patients. Conclusions. Follow-up shows transurethral electrovaporization of the prostate is an efficient and safe technique for treatment of BPH.

Original languageEnglish
Pages (from-to)191-195
Number of pages5
JournalMinerva Urologica e Nefrologica
Volume51
Issue number4
Publication statusPublished - Dec 1999

Fingerprint

Transurethral Resection of Prostate
Prostatic Hyperplasia
Prostate
Urethral Obstruction
Volatilization
Therapeutics
Catheters
Urine
Pressure

Keywords

  • Electrosurgery
  • Prostatectomy methods
  • Prostatic hyperplasia surgery

ASJC Scopus subject areas

  • Nephrology
  • Urology

Cite this

@article{f8e4e36a7b454254a858656d9037f29e,
title = "Treatment of benign prostatic hyperplasia with transurethral electrovaporization of the prostate (TUVP) using Vaportrode VE-B: Two years follow-up",
abstract = "Background. The authors report their experience on transurethral vaporization of the prostate with Vaportode for the treatment of BPH. Methods. In January 1996 we treated 24 patients suffering from cervico-urethral obstruction caused by BPH with electrovaporization of the prostate using a cutting current of between 180 and 250 Watts (average 200 Watts). Exclusion criteria was: PSA>3 ng/ml. The catheter was removed after 24 hours. Follow-up of all patients is 27 months. Twenty-three patients were evaluated. Results. Results at follow-up were; mean maximum flow (Qmax) 9.31 ml/sec preoperative was 19.5 ml/sec after 6 months, 18.3 after 12 months and 18.0 after 24 months; mean symptom score decreased from 18.1 to 10.4 after 6 months, to 3.2 after 12 months and to 4.8 after 24 months; QL index decreased from 4.6 to 2.3 at 6 months, to 1.4 after 12 months and 24 months; the average avoiding pressure decreased from 62.8 cm/H2O to 23.2 cm/H2O after 6 months, to 21.2 after 12 months and to 23.8 after 24 months. There was no post voiding residual urine 2 days after treatment in all patients. Conclusions. Follow-up shows transurethral electrovaporization of the prostate is an efficient and safe technique for treatment of BPH.",
keywords = "Electrosurgery, Prostatectomy methods, Prostatic hyperplasia surgery",
author = "M. Diana and M. Schettini and M. Gallucci",
year = "1999",
month = "12",
language = "English",
volume = "51",
pages = "191--195",
journal = "Minerva Urologica e Nefrologica",
issn = "0393-2249",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "4",

}

TY - JOUR

T1 - Treatment of benign prostatic hyperplasia with transurethral electrovaporization of the prostate (TUVP) using Vaportrode VE-B

T2 - Two years follow-up

AU - Diana, M.

AU - Schettini, M.

AU - Gallucci, M.

PY - 1999/12

Y1 - 1999/12

N2 - Background. The authors report their experience on transurethral vaporization of the prostate with Vaportode for the treatment of BPH. Methods. In January 1996 we treated 24 patients suffering from cervico-urethral obstruction caused by BPH with electrovaporization of the prostate using a cutting current of between 180 and 250 Watts (average 200 Watts). Exclusion criteria was: PSA>3 ng/ml. The catheter was removed after 24 hours. Follow-up of all patients is 27 months. Twenty-three patients were evaluated. Results. Results at follow-up were; mean maximum flow (Qmax) 9.31 ml/sec preoperative was 19.5 ml/sec after 6 months, 18.3 after 12 months and 18.0 after 24 months; mean symptom score decreased from 18.1 to 10.4 after 6 months, to 3.2 after 12 months and to 4.8 after 24 months; QL index decreased from 4.6 to 2.3 at 6 months, to 1.4 after 12 months and 24 months; the average avoiding pressure decreased from 62.8 cm/H2O to 23.2 cm/H2O after 6 months, to 21.2 after 12 months and to 23.8 after 24 months. There was no post voiding residual urine 2 days after treatment in all patients. Conclusions. Follow-up shows transurethral electrovaporization of the prostate is an efficient and safe technique for treatment of BPH.

AB - Background. The authors report their experience on transurethral vaporization of the prostate with Vaportode for the treatment of BPH. Methods. In January 1996 we treated 24 patients suffering from cervico-urethral obstruction caused by BPH with electrovaporization of the prostate using a cutting current of between 180 and 250 Watts (average 200 Watts). Exclusion criteria was: PSA>3 ng/ml. The catheter was removed after 24 hours. Follow-up of all patients is 27 months. Twenty-three patients were evaluated. Results. Results at follow-up were; mean maximum flow (Qmax) 9.31 ml/sec preoperative was 19.5 ml/sec after 6 months, 18.3 after 12 months and 18.0 after 24 months; mean symptom score decreased from 18.1 to 10.4 after 6 months, to 3.2 after 12 months and to 4.8 after 24 months; QL index decreased from 4.6 to 2.3 at 6 months, to 1.4 after 12 months and 24 months; the average avoiding pressure decreased from 62.8 cm/H2O to 23.2 cm/H2O after 6 months, to 21.2 after 12 months and to 23.8 after 24 months. There was no post voiding residual urine 2 days after treatment in all patients. Conclusions. Follow-up shows transurethral electrovaporization of the prostate is an efficient and safe technique for treatment of BPH.

KW - Electrosurgery

KW - Prostatectomy methods

KW - Prostatic hyperplasia surgery

UR - http://www.scopus.com/inward/record.url?scp=0033291483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033291483&partnerID=8YFLogxK

M3 - Article

C2 - 10812903

AN - SCOPUS:0033291483

VL - 51

SP - 191

EP - 195

JO - Minerva Urologica e Nefrologica

JF - Minerva Urologica e Nefrologica

SN - 0393-2249

IS - 4

ER -